Can we Boost Emicizumab Without Increasing Thrombosis Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn:
”Can we boost emicizumab without increasing thrombosis risk?
Emicizumab transformed hemophilia A care.
But breakthrough bleeding still happens, and treatment options remain imperfect.
A new RPTH study explores a provocative idea:
What if adding low-dose FIX plus FX together could safely enhance emicizumab-driven coagulation?
Here’s the key signal:
Combined FIX/FX supplementation restored coagulation potential to near-normal levels in vitro, in patient samples, and in hemophilia A mice.
Why this is biologically plausible:
- Emicizumab works by bridging FIXa and FX
- More FIX + FX to more ternary complex formation
- ~2× increase in FIX–emicizumab–FX complexes predicted
- Faster clot formation and reduced bleeding in vivo
- Thrombotic markers did not increase in animal models
Translation:
Rather than pushing bypassing agents harder, we may be able to optimize the emicizumab pathway itself.
Big questions for clinicians and researchers:
- Could FIX+FX become an alternative to rFVIIa for breakthrough bleeds?
- Could this strategy reduce treatment burden and dosing frequency?
- How do we balance enhanced hemostasis with real-world thrombosis risk?”
Title: Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
Authors: Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Find the Full Article on RPTH.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management